CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $213.73M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 5.78: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.38%Above 5Y avg (2.09%)
Annual Rate
JPY 18.00Paid annual
Payout Ratio
20.2%Sustainable
Next Ex-Dividend
Jun 29, 2027
The reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2025, balance sheet FY2024, cash-flow statement FY2024. Each figure below is labelled with the year it comes from.
Financials view
Market Capitalization
33.61BJPY213.73M · vs all stocks (USD)
Trailing P/E
8.50xRevenue (TTM)
24.68BJPY156.93M · vs all stocks (USD)
Profit Margin
15.19%Beta
0.5160xvs all stocks
52-Week Change
-9.01%vs all stocks
Market Capitalization
33.61BJPY213.73M · vs all stocks (USD)
Enterprise Value
17.63BJPY112.08M · vs all stocks (USD)
Trailing P/E
8.50xForward P/E
9.09xPEG Ratio
0.7893xPrice to Sales (TTM)
1.29xPrice to Book (MRQ)
1.02xEnterprise to Revenue
0.7140xEnterprise to EBITDA
2.89xProfit Margin
15.19%Operating Margin
14.12%Return on Assets (TTM)
9.05%Return on Equity (TTM)
12.64%Revenue (TTM)
24.68BJPY156.93M · vs all stocks (USD)
Revenue per Share (TTM)
585.94JPYUpdated Sep 22, 2026Quarterly Revenue Growth
12.30%Gross Profit (TTM)
8.00BJPY50.90M · vs all stocks (USD)
EBITDA (TTM)
6.09BJPY38.73M · vs all stocks (USD)
Net Income (TTM)
3.75BJPY23.84M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
2.70%Operating Cash Flow (TTM)
7.59BJPY48.28M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
3.65BJPY23.23M · vs all stocks (USD)
Trailing Annual Dividend Rate
18.00JPYUpdated Sep 22, 2026Trailing Annual Dividend Yield
2.38%vs all stocks
5-Year Average Dividend Yield
2.09%vs all stocks
Payout Ratio
20.22%EPS (Basic)
86.38JPYFY2025 · Jun 30, 2025EPS (Diluted)
86.38JPYFY2025 · Jun 30, 2025Basic Shares Outstanding
42.12MSharesFY2025 · Jun 30, 2025Diluted Shares Outstanding
42.12MSharesFY2025 · Jun 30, 2025Operating Cash Flow
4.46BJPYFY2024 · Jun 30, 2024Cash & Cash Equivalents (End of Period)
13.20BJPYFY2024 · Jun 30, 2024Starting Profit (CF Statement)
4.37BJPYFY2024 · Jun 30, 2024Other Non-cash Items
-69.62MJPYFY2024 · Jun 30, 2024Change in Accounts Receivable (CF)
-42.25MJPYFY2024 · Jun 30, 2024Change in Other Assets/Liabilities
203.03MJPYFY2024 · Jun 30, 2024Purchase of Investments
-336.01MJPYFY2024 · Jun 30, 2024Sale of Investments
308.01MJPYFY2024 · Jun 30, 2024Other Investing Activity
-1.44BJPYFY2024 · Jun 30, 2024Net Investing Cash Flow
-1.47BJPYFY2024 · Jun 30, 2024Long-term Debt Payments
-325.90MJPYFY2024 · Jun 30, 2024Net Short-term Debt Issuance
10.00MJPYFY2024 · Jun 30, 2024Common Dividends Paid
-475.38MJPYFY2024 · Jun 30, 2024Other Financing Charges
-40.77MJPYFY2024 · Jun 30, 2024Net Financing Cash Flow
795.25MJPYFY2024 · Jun 30, 2024Shares Outstanding
42.12MSharesUpdated Sep 22, 2026Float Shares
12.67MSharesUpdated Sep 22, 2026% Held by Insiders
67.97%vs all stocks
% Held by Institutions
6.77%vs all stocks
Total Cash (MRQ)
17.58BJPY111.79M · vs all stocks (USD)
Total Cash per Share (MRQ)
417.40JPYUpdated Sep 22, 2026Total Debt (MRQ)
3.32BJPY21.12M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1065xCurrent Ratio (MRQ)
3.64xBook Value per Share (MRQ)
740.30JPYUpdated Sep 22, 2026Total Assets
32.00BJPY203.51M · vs all stocks (USD)
Total Current Assets
24.78BJPYFY2024 · Jun 30, 2024Total Liabilities
6.95BJPYFY2024 · Jun 30, 2024Total Non-current Assets
7.23BJPYFY2024 · Jun 30, 2024Total Non-current Liabilities
1.98BJPYFY2024 · Jun 30, 2024Total Current Liabilities
4.98BJPYFY2024 · Jun 30, 2024Cash & Cash Equivalents
13.95BJPYFY2024 · Jun 30, 2024Accounts Receivable
3.80BJPYFY2024 · Jun 30, 2024Inventory
2.27BJPYFY2024 · Jun 30, 2024Accounts Payable
1.49BJPYFY2024 · Jun 30, 2024Short-term Debt
1.23BJPYFY2024 · Jun 30, 2024Other Current Liabilities
1.48BJPYFY2024 · Jun 30, 2024Long-term Debt
1.59BJPYFY2024 · Jun 30, 2024Other Non-current Liabilities
79.19MJPYFY2024 · Jun 30, 2024Common Stock (Book)
1.34BJPYFY2024 · Jun 30, 2024Retained Earnings
22.64BJPYFY2024 · Jun 30, 2024Total Shareholders' Equity
25.05BJPY159.30M · vs all stocks (USD)
Treasury Stock
407.00KJPYFY2024 · Jun 30, 202452-Week Low
737.00JPYUpdated Sep 22, 202652-Week High
919.00JPYUpdated Sep 22, 202652-Week Change
-9.01%vs all stocks
Beta
0.5160xvs all stocks
50-Day MA
768.76JPYUpdated Sep 22, 2026200-Day MA
811.60JPYUpdated Sep 22, 2026Avg 10-Day Volume
46.66KSharesUpdated Sep 22, 2026Avg 30-Day Volume
54.88KSharesUpdated Sep 22, 2026Diluted EPS (TTM)
89.02JPYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.78: safe zoneNotable
Altman Z-Score: 5.78
High earnings qualityNotable
Earnings Quality Score: 1.21
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $213.73M, lower than 95% of all stocks globallySignificant
Market cap (USD): 213,726,229.358Global P5: 275,556,405.438
Levered free cash flow is $23.23M, above the global median of $18.73MNotable
Levered free cash flow (USD): 23,226,645.521Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Eledon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Foghorn Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eubiologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anavex Life Sciences Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
NextBioMedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Compass Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Samyang Biopharmaceuticals Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Humedix Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Minerva Neurosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking